Dengue vaccine tetravalent - Sanofi Pasteur

Drug Profile

Dengue vaccine tetravalent - Sanofi Pasteur

Alternative Names: ChimeriVax Tetravalent Dengue Vaccine; ChimeriVax-DEN1-4; ChimeriVax-Dengue; CYD dengue vaccine; CYD dengue vaccine - Sanofi; CYD-4444; CYD-5553; CYD-5555; CYD-TDV; Dengue fever vaccine - Sanofi; Dengue vaccine recombinant tetravalent - Sanofi; Dengue vaccine tetravalent - Sanofi; Dengue virus vaccine - Sanofi; Dengvaxia; Live, attenuated, dengue serotype 1, 2, 3, 4 virus vaccine; Tetravalent CYD 1,2,3,4 dengue; Tetravalent dengue vaccine - Sanofi; TV-CYD

Latest Information Update: 11 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Acambis; Sanofi Pasteur
  • Developer Sanofi Pasteur
  • Class Attenuated vaccines; Dengue vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Dengue

Most Recent Events

  • 04 Dec 2017 Withdrawn for Dengue (In children, In infants, Prevention) in Philippines (SC)
  • 29 Nov 2017 Sanofi intends to propose label information update to National regulatory agencies for dengue vaccine tetravalent (Dengvaxia)
  • 12 Dec 2016 Sanofi plans a phase III trial in Dengue (In children, In adolescents) in Malaysia (NCT02993757)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top